Background and Objectives: The clinical benefits of stem cell therapy have been reported in patients with peripheral arterial occlusive disease. However, those studies had no standard reporting system to assess the outcomes, so we made a scoring system and assessed the outcomes of the limbs that underwent whole bone marrow stem cell (WBMSC) therapy. Methods and Results: Between July 4 and June 2009, 90 limbs of 67 patients with symptomatic thromboangiitis obliterans (TAO) were enrolled. Autologous whole bone marrow was implanted into the limb by intramuscular injections. The primary outcomes were defined by the clinical and angiographic improvement in all the limbs and the secondary outcomes were the clinical improvement and the amputation-free rates in the critical ischemic limbs (CILs). Clinical improvement and angiographic improvement was observed in 55.6% and 43.2% of all the limbs and in 50% and 50% of the CILs, respectively. The 1, 3 and 5-year amputation-free rates were 91.9%, 88.5% and 84.6% for all the limbs, respectively, and 83.9%, 77.5% and 70.4% for the CILs, respectively. A history of sympathectomy/sympathetic block was shown to be a negative prognostic factor for clinical improvement in all the limbs and in the CILs. In addition, a history of sympathetic block/sympathectomy and the smoking state were the major predictors of amputation for the CILs. Conclusions: This study indicated that autologous WMBSC therapy improves the clinical status and reduces amputation factors in the limbs with symptomatic TAO and a history of sympathetic block/sympathectomy and the smoking state are useful prognostic factors.
Introduction
Several studies have recently reported that cell therapy using stem cells induces the development of new collateral vessels and it improves the ischemic symptoms in patients with Thromboangiitis obliterans (TAO, Buerger's disease) (1) (2) (3) (4) . However, there are several limitations to directly apply stem cell therapy into the clinical field. First, most of the previous studies have had a small number of subjects and they reported only the short-term results. Second, a standardized reporting system is lacking for assessing the outcomes. Third, the ideal source and types of stem cells and their amount and route of administration have not been established. Most of all, as a source of stem Increased diameter and length of the pre-existing collateral vessels cells, the majority of studies used autologous bone marrow-derived or peripheral blood-derived mononuclear cells (3, (5) (6) (7) (8) . However, the isolation of mononuclear cells from bone marrow or peripheral blood is highly complex and expensive and there is a potential danger of contamination. We have previously reported that autologous whole bone marrow stem cell (WBMSC) therapy is a simple, safe and effective strategy to induce angiogenesis in patients with TAO (1). TAO is defined as a nonatherosclerotic, segmental inflammatory disease that commonly affects the small and medium sized arteries of the legs and/or arms (9) . The symptoms of TAO are characterized by limb ischemia, ulcer or gangrene, and TAO occurs in young smokers before the age of 45 years. The exact cause remains unknown; however, it is known that the use of tobacco is strongly associated with the initiation and progression of disease (9) (10) (11) . Even though the only definitive therapy for TAO is cessation of smoking, the presence of ischemic symptoms requires additional treatment modalities, including revascularization procedures. However, revascularization procedures such as a bypass operation or percutaneous transluminal angioplasty are frequently not feasible and they are often unsuccessful because of the diffuse segmental involvement and the distal nature of the disease (2) .
In the present study, we have focused on assessing the long-term clinical outcomes, based on the clinically relevant findings, of autologous WBMSC therapy in patients with TAO. Moreover, a newly developed scoring system that is composed of 'recanlization of run-off vessels', 'angiogenesis' and 'arteriogenesis' was applied to evaluate the angiographic outcome after WBMSC therapy ( Table 1) .
The primary outcomes were defined by the clinical and angiographic improvement in all the limbs, and the secondary outcomes were determined by the clinical improvement and the amputation-free rates in the critical ischemic limbs (CILs). In addition, we analyzed the predisposing factors that affect the clinical improvement and amputation. 
Materials and Methods

Patients population
Between July 2004 and June 2009, a total of 94 limbs (69 patients) with TAO and intermittent claudication, ischemic rest pain or tissue loss for a minimum of 2 weeks underwent WBMSC therapy, and these limbs were considered to not be suitable candidates for revascularization procedures. It was recommended that all the patients who were to undergo WBMSC therapy continue their medications. TAO was diagnosed by the clinical diagnostic criteria suggested by Shionoya (12) . The exclusion criteria were a diagnosis of atherosclerotic peripheral arterial occlusive disease, signs of acute inflammation, a previous (less than 5 years) or current history of malignant diseases, and refusal or inability to give informed consent. The patients' eligibility for WBMSC therapy was confirmed by the Samsung Vascular Disease Team, which was composed of cardiologists, interventional radiologists and vascular surgeons. This prospective study received institutional review board approval and we obtained written informed consent from all the patients for participation in the study.
Study protocol
The ankle-brachial index (ABI), the toe brachial index (TBI) and the digital subtraction angiography of the lower extremities were preoperatively examined. All the angiographies were performed at 3 days before and 6 months after WBMSC therapy and the same protocol was used that strictly fixed the force of contrast injection, the amount of contrast media and the position of the patients and the catheter tip. In addition, 75μg of recombinant human granulocyte colony stimulating factor (rhG-CSF, Cheil Jedang, Korea) was subcutaneously injected each day for 3 days before WBMSC therapy and the rhG-CSF dosage was adjusted daily to maintain a white blood cell count around 20,000 cells/ml. Peripheral blood samples were obtained daily for examining the count of the peripheral mononuclear cells and the levels of CD34 and CD133 molecules in the sera, which represented the potential endothelial progenitor cells (EPCs). Flow cytometric analysis was performed after staining the mononuclear cells with CD34-fluorescein isothiocyanate and CD133-phosphatidylethanolamine monoclonal antibodies (BD Pharmingen, San Diego, CA, USA).
On the day of the therapy, the patients were placed in the prone position under general or spinal anesthesia, and then 20 ml of autologous whole bone marrow was aspirated from the posterior superior iliac spine, and this was next split into 1 ml aliquots using 2 mm syringes. Approximately 1 ml of whole bone marrow was implanted into the calf muscles and the muscles around the run-off vessels by multiple injections (about 20 times). The procedures were finished after placing a compression dressing on the injection sites (Fig. 1) .
We followed up the patients at 1, 3, 6 and 12 months and every 1 year thereafter. The status of the wound, the development of new ischemic foot lesion, amputation, the pain-free walking distance, the ABI and the TBI were examined at every visit. On July 2009, the final information for the clinical outcomes was confirmed by a direct telephone survey, which was performed for all the patients who underwent WBMSC therapy.
Study outcomes and definitions
In present study, the primary outcomes were defined as the overall clinical and angiographic improvement in all the limbs. The secondary outcomes were determined based on the clinical improvement and the amputation in the CILs.
The clinical and angiographic outcomes were divided into 'aggravation', 'no change' and 'improvement' ( Table  1 ). The clinical improvement was defined as complete relief of ischemic rest pain without the need for analgesics or complete wound healing with or without planned removal of the non-viable tissue in the CILs. The clinical outcome for intermittent claudication was determined as the significant changes of the pain-free walking distance at the last follow-up as compared to that at baseline. In contrast, the aggravation of the clinical outcome was represented by the development of new ischemic foot lesion or any amputation due to aggravation of the wound after WBMSC therapy ( Table 1 ). The angiographic outcomes were assessed by three categories; 1) recanalization of the major run-off vessels, 2) angiogenesis (the development of new collateral vessels) and 3) arteriogenesis (the increased diameter or length of the pre-existing collateral vessels) ( Table 1) . Each category was scored from '-2' to '2' according to the degree of neovascularization and this was reviewed by 1 experienced radiologist. The angiographic outcomes were also defined as 'aggravation', 'no change' and 'improvement' by the cut-off values '0' and '1' that showed the statistically significant change of the sum of each category from baseline.
Statistics
The statistically significant changes of the pain-free 
Results
The patients' characteristics and demographic data From July 2004 to June 2009, a total of 94 limbs (69 patients) with TAO underwent WBMSC therapy. Among these patients, 1 patient (2 limbs) who underwent WBMSC therapy due to non-healing gangrenous lesions in both feet committed suicide after 6 months of WBMSC therapy and the final information of 1 patient (2 limbs) could not be obtained by telephone survey. Therefore, 90 limbs of 67 patients were included in this study.
The clinical and demographic data is shown in Table  2 . All the patients (n=67) were males and their mean age was 39.8±7.9 years and the mean duration of follow-up was 29.3±18.1 months (range: 2±61 months). The duration of ischemic symptoms was generally more than 12 months for the limbs with intermittent claudication and it was between 1 and 6 months for the CIL. Approximately 11% of the patients in the claudication and CIL groups had a history of revascularization procedures. Previous histories of amputation and sympathetic block/sympathectomy were more prevalent in the CIL group that those in the claudication group (2.5% vs. 17.4%, 2.3% vs. 30.4%, respectively). Four limbs that had a history of diabetes mellitus at the time of WBMSC therapy did not have diabetes mellitus at the time of diagnosing TAO. More than half of the included study population stopped smoking before WBMSC therapy, but a quarter continued smoking through the follow-up period ( Table 2 ). The mean ABI was similar in both groups (0.82 vs. 0.76, respectively), but the TBI in the CIL group was lower than that in the claudication group (0.45 vs. 0.12, respectively). It was considered that the relatively higher ABI, in contrast with the severe ischemic symptoms, could be attributed to the involvement of the distal small arteries below the ankle of the patients with TAO.
Procedures and safety issues
All the patients well tolerated the WBMSC therapy and no procedure-related complications were observed, such as bleeding, osteomyelitis, vascular damage and the reported adverse effects due to the thrombotic properties of rhG-CSF. However, one patient of 40 years, who had no evidence of hypertension, diabetes, hyperlipidemia, hypercoagulability or autoimmune disease, suffered myocardial infarction 25 months after WBMSC therapy, but the exact cause of his myocardial infarction remains unknown. Pre-and postoperative angiographies of the lower extremities were obtained in 37 limbs (41.1%) and no angiography-related complications occurred. The recanaliza- 3 . The cumulative amputation-free rates after autologous whole bone marrow stem cell therapy. The 1-, 3-and 5-year amputation-free rates of all the limbs were 91.9%, 88.5% and 84.6%, respectively. The 1-, 3-and 5-year amputation-free rates of the critical ischemic limbs were 83.9%, 77.5% and 70.4%, respectively. tion of the run-off vessels, the development of new collateral vessels (angiogenesis) and the increased diameter and/or length of preexisting collateral vessels (arteriogenesis) were noted in 3 (8.1%), 16 (43.2%) and 15 (40.5%) limbs, respectively (Fig. 2 ).
Primary and secondary outcomes
As the primary outcomes, clinical improvement occurred in 55.6% and angiographic improvement occurred in 43.2% of all the limbs (Fig. 3) . However, there was no significant correlation between the clinical outcome and the angiographic outcome (p=0.233). The cumulative 1-year, 3-year and 5-year amputation-free rates of all the limbs were 91.9%, 88.5% and 84.6%, respectively (Fig. 4) . During the follow-up period, major amputation was performed on only 1 limb at 5 months after WBMSC therapy due to persistent non-healing ischemic foot ulcer.
In the CIL group, clinical improvement and angiogra- phic improvement were observed in 50% and 50%, respectively. In addition, the cumulative 1-year, 3-year and 5-year amputation-free rates of the CIL group were 83.9%, 77.5% and 70.4%, respectively (Fig. 4) .
Analysis of the prognostic factors for clinical improvement and amputation
For all the limbs (n=90 limbs), our multivariate analysis indicated that a period of more than 6 months after WBMSC therapy positively affected the clinical outcome (p=0.049, 95% CI: 1.001∼14.820, Hazard ratio: 3.852) and the patients with a history of sympathetic block/sympathectomy showed a worse clinical outcome than those patients with no history of sympathetic block/sympathectomy (p=0.048, 95% CI: 0.051∼0.0990, Hazard ratio: 0.224) ( 
Analysis of the EPCs count
We analyzed the number of rhG-CSF-mobilized peripheral blood EPCs per milliliter (n=44 limbs), including the number of MNCs, CD34+, CD133+ and CD34+CD133+ cells and the number of implanted bone marrow EPCs per milliliter (n=39 limbs) ( Table 5 ). In addition, the peripheral blood and bone marrow mononuclear cell composition was analyzed by flow cytometric dot plot analysis according to the forward and side scatter (Fig. 5) . After the injection of rhG-CSF, the cell numbers of lymphocytes were highest and the cell numbers of granulocytes were lowest on day 1 (Fig. 5B) . The cell numbers of granulocytes were increased on day 1, but the cell numbers of monocytes were highest on day 2 (Fig. 5C, D) . The mean number of implanted MNCs, CD34+, CD133+ and CD34+ CD133+ cells were 4.46×10 peripheral blood and bone marrow EPCs had no significant correlation with clinical improvement (Table 5) .
Discussion
All the previous clinical studies that used stem cells for treating peripheral arterial occlusive disease had no stand-ardized reporting system to assess the outcomes, so we made up a new scoring system to assess the outcomes and we evaluated our results based on this new scoring system. Our present study indicates that autologous WBMSC therapy improved the clinical and angiographic statuses of the limbs with symptomatic TAO. To assess the long-term clinical and angiographic outcomes, we created an assessment system composed of 'aggravation', 'no change' and 'improvement'. The assessment of the long-term clinical outcome was based on the clinical status such as the change of the pain-free walking distance, relief from ischemic foot pain, complete wound healing, amputation and development of new ischemic foot lesion. To evaluate the angiographic outcome as was assessed at 6 months after WBMSC therapy, the angiographic findings were divided into 3 categories: recanalization of the run-off vessels, angiogenesis and arteriogenesis, and then each category was scored from '-2' to '+2'. In the present study, angiogenesis was defined as the sprouting of new capillaries from pre-existing vascular structures, and arteriognesis was defined as the growth of pre-existing vessels and their caliber (13) . Changes of the run-off vessels were noted in 6 limbs (3 limbs with aggravation and 3 limbs with improvement). Our suggested mechanism for the occlusion and recanalization of major run-off vessels is that the occlusion might be the result of progression of TAO and the recanalization of the occluded arteries was the result of the healing process by the stem cells.
Several previous clinical studies have been performed using autologous bone marrow derived-or peripheral blood-derived stem cells in patients with peripheral arterial occlusive disease and they reported favorable results for the ischemic signs and symptoms. In 2002, TateishiYuyama et al. (5) (the TACT study) conducted a randomized controlled study, and they demonstrated improvement in the transcutaneous oxygen pressure, resting pain and pain-free walking times during the 24 months of follow-up after the intramuscular injection of autologous bone marrow mononuclear cells in 25 patients with unilateral chronic limb ischemia. Lenk et al. (14) indicated that intra-arterial application of autologous circulating blood-derived progenitor cells improved the pain-free walking distance, the ABI and the transcutaneous oxygen pressure. Franz et al. (8) recently reported that for nine patients for whom limb amputation was recommend, 88.9% showed some level of improvement and 66.7% avoided amputation. In addition, as the long-term results after intramuscular implantation of bone marrow-derived mononuclear cells, Matoba et al. (15) assessed the 3-year safety and clinical outcomes of patients with chronic limbs ischemia (Fontaine stage III and IV, peripheral artery disease: n=74 and TAO: n=41) after they had undergone intramuscular implantation of bone marrow-derived mononuclear cells. They reported that the 3-year survival rate was 80% for the patients with atherosclerotic peripheral arterial disease and 100% for the patients with TAO, and the 3-year amputation-free rate was 60% for the patients with atherosclerotic peripheral artery disease and 91% for the patients with TAO. However, it is difficult to judge the efficacy of the stem cells therapy in these studies because they used different inclusion criteria and assessment methods, and they reported only the results for a small population.
In the present study, to assess the outcomes after WBMSC therapy, we enrolled the limbs that had only symptomatic TAO and we made a new assessment system for the outcomes. As a result, 55.6% of all the included limbs showed clinical improvement and 43.2% showed angiographic improvement. However, no statistically significant relations were found between the clinical and angiographic outcomes (p=0.206). In addition, clinical improvement and angiographic improvement occurred in 50% and 50% of the CILs, respectively. In this study, the 1-year, 3-year and 5-year amputation-free rates were 91.8%, 88.3% and 84.5% for the all limbs and 83.7%, 77.2% and 70.2% in the CILs, respectively. Moreover, major amputation above the ankle joint was performed on only 1 limb during the 5-year follow-up period. Although we have no control date for conventional therapy in the TAO limbs, when considering the reported studies that the 5-year amputation rate was about 25% and the major amputation rate was about 11% for TAO limbs (16, 17) , our results indicated that WBMSC therapy improved the clinical status and reduced the amputation rate for patients with TAO.
Matoba et al. (15) have reported that the severity of resting pain and repeated bypass surgery were the important prognostic factors for the amputation-free interval for patients with peripheral arterial disease by multivariate analysis. However, our statistical analysis revealed that a period more than 6 months after WBMSC therapy was a major determinant for clinical improvement. This finding means that a period of more than 6 months is needed to represent the clinical improvement of WBMSC therapy. A history of sympathetic block/sympathectomy was shown to be a significant prognostic factor for clinical improvement in all the limbs and in the CILs. In addition, it showed that a history of sympathetic block/sympathectomy and smoking at the time of WBMSC therapy were the most important predictors of amputation for CILs. Although the role of sympathectomy for preventing amputation or treating ischemic pain remains unclear (18) (19) (20) , some physicians have employed it to reduce severe ischemic pain and to help wound healing. Moreover, smoking is a well known major determinant for the progression of the disease and amputation in patients with TAO: the complete discontinuation of any forms of smoking and tobacco use was the most important treatment option to halt disease progression and avoid further amputation in patients with TAO (18, 21, 22) . For the CILs, our multivariate statistical results indicated that a previous history of severe ischemic pain and the smoking state were the major determinants for clinical improvement and amputation.
Most of the previous studies have used the angiographic outcome as well as the functional outcome to evaluate neovascularization after bone marrow-derived or peripheral blood-derived stem cell therapy, yet there have been no established methods for assessing neovascularization (3). The currently available angiographic studies have limitations to demonstrate angiogenesis or arteriogenesis, and especially for vessels measuring ＜200μm in diameter (23) . Our present study showed that the clinical improvement was better than the angiographic improvement, but there was no statistically significant difference between the clinical outcome and the angiographic outcome. There are two possibilities to explain why the clinical improvement was better than the angiographic improvement without statistically significant correlation. The first is that whole bone marrow might contain unknown cells and growth factors as well as stem cells that are required for neovascularization and they promote neovascularization that can not to be detected by angiography. The second is that the synergic effect of rhG-CSF-mobilization and implantation of WBMSC induces repair of the tissues that are impaired due to ischemic injury.
Moreover, most of the previous clinical studies on patients with limb ischemia have used isolated bone marrow-derived mononuclear cells or peripheral blood-derived mononuclear cells, so they could not demonstrate the ideal number of cells to obtain some benefit (5, 8, 14, 24) . Kajiguchi et al. (25) reported that the number of transplanted mononuclear cells, CD34+ cells, CD133+ cells and CD34+CD133+ cells were not significantly different between the responders and non-responders after autologous progenitor cell transplantation in patients with critical limb ischemia. In addition, no correlation between the cell number and the clinical outcomes was demonstrated in the stem cell trials for patients with myocardial infarction (26, 27) . We also tried to identity the definite numbers of different EPCs that are needed to obtain clinical improvement, but we failed to establish the numbers of the EPCs populations that are correlated with clinical improvement.
There were several limitations of our study. First of all, the major limitation was the absence of a control group to compare the outcomes after WBMSC therapy, yet it is not ethical to assign patients with symptomatic TAO to a control group. Second, all of the enrolled limbs had TAO, which is only one of many peripheral arterial occlusive diseases, so atherosclerotic peripheral occlusive diseases should be included in a future study. Third, any significant correlation between the numbers of different EPCs populations and the clinical outcome could not be found.
